Regen BioPharma Files Unaudited Financial Statements for Fiscal Year Ended September 30, 2024

Regen BioPharma, Inc., a small business issuer based in Nevada, recently reported its unaudited consolidated financial statements for the fiscal year that concluded on September 30, 2024. This disclosure was made through a Form 1-A filing with the United States Securities and Exchange Commission.

The documents exhibit a snapshot of the company’s financial status, revealing a range of figures regarding assets, liabilities, and equity for the year under review. As outlined in the financial statements, the company showcased total assets amounting to $177,611. In detail, the assets included various components such as cash, accounts receivable, prepaid expenses, and investment securities, among others.

On the liabilities front, Regen BioPharma reported total current liabilities of $5,371,640, incorporating details on accounts payable, notes payable, accrued expenses, and other financial obligations. Additionally, the stockholders’ equity (deficit) stood at ($5,194,029), reflecting the company’s financial standing in terms of common and preferred stock, additional paid-in capital, and retained earnings or deficit.

Concerning operational performance, the company’s revenues for the year summed up to $236,560, derived from various sources including related parties. However, costs and expenses totaled $654,749, resulting in an operating loss of ($418,189). The net income (loss) for the period was reported at ($867,252).

Regen BioPharma’s financial statements also detailed other aspects such as interest expenses, gains or losses on investments, and financing fees, all of which impacted the company’s overall financial picture for the year ended September 30, 2024.

The company’s financial reports have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023. This adjustment accounts for changes in the capital structure and outstanding shares.

The financial disclosures serve to provide transparency and insight into Regen BioPharma’s fiscal health, allowing stakeholders and investors to gauge the company’s performance and trajectory moving forward.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Regen BioPharma’s 8K filing here.

About Regen BioPharma

Regen BioPharma, Inc focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.